Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, United States of America.
Department of Pathology, Providence Health and Services, Portland, OR, United States of America.
PLoS One. 2021 Feb 17;16(2):e0247238. doi: 10.1371/journal.pone.0247238. eCollection 2021.
The TSA Opal multiplex immunohistochemistry (mIHC) protocol (PerkinElmer) has been used to characterize immune infiltration in human cancers. This technique allows multiple biomarkers to be simultaneously stained in a single tissue section, which helps to elucidate the spatial relationship among individual cell types. We developed and optimized two improved mIHC protocols for a 7-color panel containing 6 biomarkers (CD3, CD8, CD163, PD-L1, FoxP3, and cytokeratin (CK)) and DAPI. The only difference between these two protocols was the staining sequence of those 6 biomarkers as the first sequence is PD-L1/CD163/CD8/CK/CD3/FoxP3/DAPI and the second sequence is FoxP3/CD163/CD8/CK/CD3/PD-L1/DAPI. By comparing PD-L1/FoxP3 staining in mIHC and singleplex PD-L1/FoxP3 staining on the adjacent slide, we demonstrated that the staining sequence does not affect the staining intensity of individual biomarkers as long as a proper antigen retrieval method was used. Our study suggests that use of an antigen retrieval buffer with higher pH value (such as Tris-EDTA pH9.0) than that of the stripping buffers (such as citrate buffer pH6.0) is helpful when using this advanced mIHC method to develop panels with multiple biomarkers. Otherwise, individual biomarkers may exhibit different intensities when the staining sequence is changed. By using this protocol, we characterized immune infiltration and PD-L1 expression in head and neck squamous cell carcinoma (HNSCC), breast cancer (BCa), and non-small cell lung cancer (NSCLC) specimens. We observed a statistically significant increase in CD3+ cell populations within the stroma of NSCLC as compared to BCa and increased PD-L1+ tumor cells in HNSCC as opposed to BCa.
TSA Opal 多重免疫组化(mIHC)方案(PerkinElmer)已被用于鉴定人类癌症中的免疫浸润。该技术允许在单个组织切片中同时对多个生物标志物进行染色,有助于阐明单个细胞类型之间的空间关系。我们开发并优化了两种改进的 mIHC 方案,用于包含 6 个生物标志物(CD3、CD8、CD163、PD-L1、FoxP3 和细胞角蛋白(CK))和 DAPI 的 7 色面板。这两种方案之间的唯一区别是这 6 个生物标志物的染色顺序,第一种顺序为 PD-L1/CD163/CD8/CK/CD3/FoxP3/DAPI,第二种顺序为 FoxP3/CD163/CD8/CK/CD3/PD-L1/DAPI。通过比较 mIHC 中的 PD-L1/FoxP3 染色和相邻载玻片上的单重 PD-L1/FoxP3 染色,我们证明只要使用适当的抗原修复方法,染色顺序不会影响单个生物标志物的染色强度。我们的研究表明,在使用这种先进的 mIHC 方法开发具有多个生物标志物的面板时,使用 pH 值高于洗脱缓冲液(如柠檬酸缓冲液 pH6.0)的抗原修复缓冲液(如 Tris-EDTA pH9.0)有助于提高染色强度。否则,当改变染色顺序时,单个生物标志物可能表现出不同的强度。通过使用该方案,我们对头颈部鳞状细胞癌(HNSCC)、乳腺癌(BCa)和非小细胞肺癌(NSCLC)标本中的免疫浸润和 PD-L1 表达进行了特征描述。我们观察到 NSCLC 基质中 CD3+细胞群体的数量与 BCa 相比有统计学意义的增加,并且与 BCa 相比,HNSCC 中 PD-L1+肿瘤细胞的数量增加。